MA71325A - Inhibiteur de kras g12c pour le traitement du cancer - Google Patents
Inhibiteur de kras g12c pour le traitement du cancerInfo
- Publication number
- MA71325A MA71325A MA71325A MA71325A MA71325A MA 71325 A MA71325 A MA 71325A MA 71325 A MA71325 A MA 71325A MA 71325 A MA71325 A MA 71325A MA 71325 A MA71325 A MA 71325A
- Authority
- MA
- Morocco
- Prior art keywords
- kras
- inhibitor
- cancer treatment
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357227P | 2022-06-30 | 2022-06-30 | |
| US202363486785P | 2023-02-24 | 2023-02-24 | |
| US202363496447P | 2023-04-17 | 2023-04-17 | |
| PCT/US2023/026554 WO2024006424A1 (en) | 2022-06-30 | 2023-06-29 | Kras g12c inhibitor for treating cancer |
| EP23745331.1A EP4547251A1 (en) | 2022-06-30 | 2023-06-29 | Kras g12c inhibitor for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71325A true MA71325A (fr) | 2025-04-30 |
Family
ID=87468549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71325A MA71325A (fr) | 2022-06-30 | 2023-06-29 | Inhibiteur de kras g12c pour le traitement du cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240108618A1 (https=) |
| EP (1) | EP4547251A1 (https=) |
| JP (2) | JP7496917B2 (https=) |
| KR (1) | KR20250027777A (https=) |
| CN (1) | CN119907671A (https=) |
| CA (1) | CA3260047A1 (https=) |
| IL (1) | IL317823A (https=) |
| MA (1) | MA71325A (https=) |
| MX (1) | MX2025000105A (https=) |
| WO (1) | WO2024006424A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| BR112022022021A2 (pt) * | 2020-04-30 | 2022-12-13 | Genentech Inc | Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor |
| US20230285498A1 (en) * | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| MX2023003060A (es) * | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
-
2023
- 2023-06-29 EP EP23745331.1A patent/EP4547251A1/en active Pending
- 2023-06-29 KR KR1020257002609A patent/KR20250027777A/ko active Pending
- 2023-06-29 IL IL317823A patent/IL317823A/en unknown
- 2023-06-29 CN CN202380063188.1A patent/CN119907671A/zh active Pending
- 2023-06-29 US US18/344,134 patent/US20240108618A1/en active Pending
- 2023-06-29 WO PCT/US2023/026554 patent/WO2024006424A1/en not_active Ceased
- 2023-06-29 CA CA3260047A patent/CA3260047A1/en active Pending
- 2023-06-29 MA MA71325A patent/MA71325A/fr unknown
- 2023-06-30 JP JP2023108177A patent/JP7496917B2/ja active Active
-
2024
- 2024-05-28 JP JP2024086236A patent/JP2024112968A/ja active Pending
-
2025
- 2025-01-06 MX MX2025000105A patent/MX2025000105A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7496917B2 (ja) | 2024-06-07 |
| CN119907671A (zh) | 2025-04-29 |
| US20240108618A1 (en) | 2024-04-04 |
| CA3260047A1 (en) | 2024-01-04 |
| AU2023297941A1 (en) | 2025-01-16 |
| MX2025000105A (es) | 2025-02-10 |
| JP2024007504A (ja) | 2024-01-18 |
| KR20250027777A (ko) | 2025-02-27 |
| WO2024006424A1 (en) | 2024-01-04 |
| JP2024112968A (ja) | 2024-08-21 |
| IL317823A (en) | 2025-02-01 |
| TW202421145A (zh) | 2024-06-01 |
| EP4547251A1 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71325A (fr) | Inhibiteur de kras g12c pour le traitement du cancer | |
| MA71370A (fr) | Inhibiteurs macrocycliques de kras pour le traitement du cancer | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP3867410A4 (en) | Methods for determining treatment for cancer patients | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP3894392A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | |
| EP3908601A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP4081518A4 (en) | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP4100061A4 (en) | COMBINATION THERAPIES AND BIOMARRKERS FOR THE TREATMENT OF CANCER | |
| EP4319750A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4229048A4 (en) | Substituted acyl sulfonamides for treating cancer | |
| EP4259147A4 (en) | Combination therapies for the treatment of cancer | |
| EP3814525A4 (en) | TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS | |
| EP4373525A4 (en) | CANCER TREATMENT COMBINATIONS | |
| EP4149547A4 (en) | Compositions and methods for treating cancer | |
| EP4242207A4 (en) | Kras inhibitors for treatment of cancers | |
| MA71734A (fr) | Composés pour le traitement du cancer | |
| MA55486A (fr) | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP4263584A4 (en) | Combination therapy for the treatment of cancer | |
| EP4292596A4 (en) | METHODS AND COMBINATIONS FOR THE TREATMENT OF TUMORS |